Molecular Targeted Therapy in Ovarian Cancer

[1]  A. Tutt,et al.  Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Burger,et al.  PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  E. Lengyel,et al.  A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. , 2011, Gynecologic oncology.

[4]  M. Sasamata,et al.  Broad spectrum and potent antitumor activities of YM155, a novel small‐molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models , 2011, Cancer science.

[5]  Mélanie Schmidt,et al.  Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers , 2011, Archives of Gynecology and Obstetrics.

[6]  A. Oza,et al.  A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Igor Goryanin,et al.  Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition. , 2011, Cellular signalling.

[8]  David D. L. Bowtell,et al.  The genesis and evolution of high-grade serous ovarian cancer , 2010, Nature Reviews Cancer.

[9]  Gunnar B. Kristensen,et al.  A randomized phase II clinical trial of the SRC inhibitor saracatinib (AZD0530) and carboplatin plus paclitaxel (C plus P) versus C plus P in patients (pts) wiht advanced platinum-sensitive epithelial ovarian cancer (eoc) , 2010 .

[10]  A. Oza,et al.  ICON7: A PHASE III RANDOMISED GYNAECOLOGIC CANCER INTERGROUP TRIAL OF CONCURRENT BEVACIZUMAB AND CHEMOTHERAPY FOLLOWED BY MAINTENANCE BEVACIZUMAB, VERSUS CHEMOTHERAPY ALONE IN WOMEN WITH NEWLY DIAGNOSED EPITHELIAL OVARIAN (EOC), PRIMARY PERITONEAL (PPC) OR FALLOPIAN TUBE CANCER (FTC) , 2010 .

[11]  M. Friedlander,et al.  A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. , 2010, Gynecologic oncology.

[12]  B. Karlan,et al.  PHASE II STUDY OF THE ORAL PARP INHIBITOR OLAPARIB (AZD2281) VERSUS LIPOSOMAL DOXORUBICIN IN OVARIAN CANCER PATIENTS WITH BRCA1 AND/OR BRCA2 MUTATIONS , 2010 .

[13]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[14]  Arijit Chakravarty,et al.  Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics , 2010, Molecular Cancer Therapeutics.

[15]  B. Karlan,et al.  Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  G. Mills,et al.  Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Gordon B Mills,et al.  Personalizing therapy for ovarian cancer: BRCAness and beyond. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  F. Spinella,et al.  Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer. , 2010, Canadian journal of physiology and pharmacology.

[19]  B. Monk,et al.  Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  B. Mayer,et al.  The role of c-FLIP(L) in ovarian cancer: chaperoning tumor cells from immunosurveillance and increasing their invasive potential. , 2010, Gynecologic oncology.

[21]  A. Schneeweiss,et al.  Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study. , 2010 .

[22]  Carlos Caldas,et al.  Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.

[23]  H. Putter,et al.  Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  H. Kantarjian,et al.  Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells , 2010, Leukemia & lymphoma.

[25]  A. Oza,et al.  Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium , 2010, International Journal of Gynecologic Cancer.

[26]  A. Mes-Masson,et al.  Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma , 2010, The Journal of pathology.

[27]  S. Steinberg,et al.  Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2 , 2010, Clinical Cancer Research.

[28]  B. Tsang,et al.  Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein , 2010, Oncogene.

[29]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[30]  Robert C. Bast,et al.  The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.

[31]  G. Jayson,et al.  A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  V. Velculescu,et al.  Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. , 2009, The American journal of pathology.

[33]  K. Devarajan,et al.  Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. , 2009, Gynecologic oncology.

[34]  D. Alberts,et al.  Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Wei Hu,et al.  Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. , 2009, American journal of obstetrics and gynecology.

[36]  Christopher D. Scharer,et al.  Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells , 2008, Journal of Translational Medicine.

[37]  E. Small,et al.  Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[39]  P. Sabbatini,et al.  A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. , 2008, Gynecologic oncology.

[40]  M. Gore,et al.  A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers , 2008, British Journal of Cancer.

[41]  C. Muller,et al.  Phase I/II lapatinib plus carboplatin and paclitaxel in stage III or IV relapsed ovarian cancer patients , 2008 .

[42]  R. Bast,et al.  A phase IIa study of a sequential regimen using azacitidine to reverse platinum resistance to carboplatin in patients with platinum resistant or refractory epithelial ovarian cancer , 2008 .

[43]  A. Harris,et al.  A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors , 2008 .

[44]  J. Carmichael,et al.  AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study , 2008 .

[45]  A. Oza,et al.  A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial , 2008 .

[46]  Zhi-yu Wang,et al.  Inhibition of lysophosphatidic acid receptor-2 expression by RNA interference decreases lysophosphatidic acid-induced urokinase plasminogen activator activation, cell invasion, and migration in ovarian cancer SKOV-3 cells. , 2008, Croatian medical journal.

[47]  Zhen Lu,et al.  Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down‐regulated in human ovarian cancers by loss of heterozygosity and promoter methylation , 2008, Cancer.

[48]  S. Kaye,et al.  The Bcl-2/Bcl-XL Family Inhibitor ABT-737 Sensitizes Ovarian Cancer Cells to Carboplatin , 2007, Clinical Cancer Research.

[49]  Howard Mackey,et al.  Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Michael W Sill,et al.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  J. Bradner,et al.  8-Benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic Acid (SD-1008), a Novel Janus Kinase 2 Inhibitor, Increases Chemotherapy Sensitivity in Human Ovarian Cancer Cells , 2007, Molecular Pharmacology.

[52]  C. Rancourt,et al.  Malignant ascites protect against TRAIL‐induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells , 2007, International journal of cancer.

[53]  M. Rettenmaier,et al.  A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer , 2006, International Journal of Gynecologic Cancer.

[54]  R. Buller,et al.  A phase II, open-label study of ispinesib (SB-715992) in patients with platinum/taxane refractory or resistant relapsed ovarian cancer , 2007 .

[55]  A. Oza,et al.  VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study , 2007 .

[56]  M. Gore,et al.  Maintenance erlotinib (E) following first-line treatment with docetaxel, carboplatin and erlotinib in patients with ovarian carcinoma , 2007 .

[57]  H. Gabra,et al.  Antiestrogen Therapy Is Active in Selected Ovarian Cancer Cases: The Use of Letrozole in Estrogen Receptor–Positive Patients , 2007, Clinical Cancer Research.

[58]  Liz Y. Han,et al.  Curcumin Inhibits Tumor Growth and Angiogenesis in Ovarian Carcinoma by Targeting the Nuclear Factor-κB Pathway , 2007, Clinical Cancer Research.

[59]  A. Fields,et al.  Protein kinase Cι: Human oncogene, prognostic marker and therapeutic target , 2007 .

[60]  D. Alberts,et al.  A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer , 2006, International Journal of Gynecologic Cancer.

[61]  H. Burris,et al.  A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. , 2007, Gynecologic oncology.

[62]  Barry Rosen,et al.  Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. , 2006, Journal of the National Cancer Institute.

[63]  R. Bast,et al.  The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis , 2006, Cancer.

[64]  Molly Brewer,et al.  Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  Liz Y. Han,et al.  Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. , 2006, Cancer research.

[66]  M. Bookman,et al.  GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  Tian-Li Wang,et al.  Notch3 gene amplification in ovarian cancer. , 2006, Cancer research.

[68]  Sandya Liyanarachchi,et al.  Prognostic DNA Methylation Biomarkers in Ovarian Cancer , 2006, Clinical Cancer Research.

[69]  Anil K Sood,et al.  Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer , 2006, Cancer biology & therapy.

[70]  D. Bodurka,et al.  Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. , 2006, Gynecologic oncology.

[71]  Liz Y. Han,et al.  The Clinical Relevance of Stromal Matrix Metalloproteinase Expression in Ovarian Cancer , 2006, Clinical Cancer Research.

[72]  L. Klampfer,et al.  Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. , 2006, Current cancer drug targets.

[73]  G. Stamp,et al.  Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  Wing H Wong,et al.  Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. , 2005, Cancer research.

[75]  D. Coppola,et al.  Significance of Fas receptor protein expression in epithelial ovarian cancer. , 2005, Human pathology.

[76]  A. Godwin,et al.  Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study , 2005, Clinical Cancer Research.

[77]  R. Baserga.  The insulin-like growth factor-I receptor as a target for cancer therapy , 2005, Expert opinion on therapeutic targets.

[78]  Anil K Sood,et al.  Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[79]  Wenjun Cheng,et al.  Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract , 2005, Nature Medicine.

[80]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[81]  Yiling Lu,et al.  Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma* , 2005, Molecular & Cellular Proteomics.

[82]  S. Mandrekar,et al.  A Phase I Trial of the Novel Farnesyl Protein Transferase Inhibitor, BMS-214662, in Combination with Paclitaxel and Carboplatin in Patients with Advanced Cancer , 2005, Clinical Cancer Research.

[83]  Stephen S. Taylor,et al.  Aurora-kinase inhibitors as anticancer agents , 2004, Nature Reviews Cancer.

[84]  Wayne A. Phillips,et al.  Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.

[85]  Rosemary Steinmetz,et al.  Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation. , 2004, Molecular endocrinology.

[86]  M. Ranson,et al.  Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase. , 2004, Molecular cancer therapeutics.

[87]  B. Tsang,et al.  Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro , 2004, Oncogene.

[88]  G. Mills,et al.  Lysophosphatidic acid production and action: Validated targets in cancer? , 2004, Journal of cellular biochemistry.

[89]  William R Sellers,et al.  The biology and clinical relevance of the PTEN tumor suppressor pathway. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  P. Horák,et al.  Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. , 2004, Gynecologic oncology.

[91]  J. Gustafsson,et al.  Estrogen and progesterone receptors in ovarian epithelial tumors , 2004, Molecular and Cellular Endocrinology.

[92]  R. Edwards,et al.  Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study , 2004, International Journal of Gynecologic Cancer.

[93]  Wenjun Cheng,et al.  Activated Signal Transducer and Activator of Transcription (STAT) 3 , 2004, Cancer Research.

[94]  I. Shih,et al.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.

[95]  M. Gore,et al.  A Multicenter Phase I Gene Therapy Clinical Trial Involving Intraperitoneal Administration of E1A-Lipid Complex in Patients with Recurrent Epithelial Ovarian Cancer Overexpressing HER-2/neu Oncogene , 2004, Clinical Cancer Research.

[96]  S. Frisch.  E1A as a Tumor Suppressor Gene , 2004, Clinical Cancer Research.

[97]  N. Umesaki,et al.  Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion* , 2004, Journal of Biological Chemistry.

[98]  W. Hahn,et al.  A Genetically Defined Model for Human Ovarian Cancer , 2004, Cancer Research.

[99]  R. Bast,et al.  Overexpression of MEKK3 Confers Resistance to Apoptosis through Activation of NFκB* , 2004, Journal of Biological Chemistry.

[100]  W. Hahn,et al.  In situ human telomerase reverse transcriptase expression pattern in normal and neoplastic ovarian tissues. , 2004, Oncology reports.

[101]  H. Nagawa,et al.  Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis , 2004, Modern Pathology.

[102]  Luke Hughes-Davies,et al.  EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer , 2003, Cell.

[103]  C. Marth,et al.  Why did p53 gene therapy fail in ovarian cancer? , 2003, The Lancet. Oncology.

[104]  C. Mathew,et al.  Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors , 2003, Nature Medicine.

[105]  E. Eisenhauer,et al.  Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116). , 2003, Gynecologic oncology.

[106]  G. Mills,et al.  The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. , 2003, Cancer research.

[107]  K. Darcy,et al.  Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  N. Ferrara,et al.  Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. , 2002, The American journal of pathology.

[109]  Kathleen R. Cho,et al.  Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. , 2002, Cancer research.

[110]  B. Karlan,et al.  A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer , 2002, Cancer Gene Therapy.

[111]  F. Spinella,et al.  Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. , 2002, Molecular pharmacology.

[112]  Jiayuh Lin,et al.  Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells , 2001, Oncogene.

[113]  S. Inoue,et al.  A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization. , 2001, Gynecologic oncology.

[114]  Robert Brown,et al.  Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. , 2001, The American journal of pathology.

[115]  B N Bundy,et al.  Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  Y. Sugisaki,et al.  Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma , 2000, British Journal of Cancer.

[117]  P. Meltzer,et al.  Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[118]  J. Herman,et al.  Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. , 2000, Journal of the National Cancer Institute.

[119]  G. Mills,et al.  In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[120]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[121]  G. Mills,et al.  Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[122]  Shuk-Mei Ho,et al.  Expression of human estrogen receptor-α and -β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells , 1999 .

[123]  A. Skubitz,et al.  CD44 and β1 Integrin Mediate Ovarian Carcinoma Cell Adhesion to Peritoneal Mesothelial Cells , 1999 .

[124]  P. Natali,et al.  Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. , 1999, Cancer research.

[125]  R. Steele,et al.  Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. , 1997, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[126]  P. McCann,et al.  Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. , 1997, Pharmacology & therapeutics.

[127]  S. Cannistra,et al.  In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. , 1997, Cancer research.

[128]  P. Sismondi,et al.  The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. , 1996, British Journal of Cancer.

[129]  W. Herman,et al.  Nuclear signaling by endothelin-1. A Ras pathway for activation of the c-fos serum response element , 1995, The Journal of Biological Chemistry.

[130]  F. Balkwill,et al.  A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. , 1993, Cancer research.

[131]  K. Hatch,et al.  Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A gynecologic oncology group study of second‐line therapy in 105 patients , 1991, Cancer.

[132]  R. Bast,et al.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983, The New England journal of medicine.

[133]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[134]  J Folkman,et al.  Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.

[135]  R. Messmann,et al.  PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[136]  J. Dungan.  Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer , 2010 .

[137]  J. Thigpen.  Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer , 2009 .

[138]  G. Mills,et al.  Ovarian cancer: homeobox genes, autocrine/paracrine growth, and kinase signaling. , 2006, The international journal of biochemistry & cell biology.

[139]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[140]  J. M. Kim,et al.  Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. , 2001, Endocrinology.

[141]  S. Mok,et al.  Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[142]  A. Skubitz,et al.  CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells. , 1999, The American journal of pathology.

[143]  Joe W. Gray,et al.  PIK3CA is implicated as an oncogene in ovarian cancer , 1999, Nature Genetics.

[144]  P. Humphrey,et al.  Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. , 1993, Obstetrics and gynecology.